Published on 20 Feb 2024 on Zacks via Yahoo Finance
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
BeiGene BGNE is expected to report its fourth-quarter 2023 results soon.
BeiGene currently markets three internally discovered oncology products, including BTK inhibitor, Brukinsa(zanubrutinib), in the United States, China, EU, United Kingdom and additional international markets. The company markets its other products like anti-PD-1 antibody, tislelizumab, in the EU and China, and PARP inhibitor, pamiparib, only in China.
The company has also in-licensed the rights to distribute an additional 14 approved medicines for the China market, which contributes to its top line.